Interações de Cladribina

Antiviral and antiretroviral drugs: Avoid concomitant use. (bula de Cladribina, Interações medicamentosas)

Antiviral and antiretroviral drugs: Avoid concomitant use. (bula de Cladribina, Interações medicamentosas)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (bula de Cladribina, Interações medicamentosas)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (bula de Cladribina, Interações medicamentosas)

Prevention or Management Avoid co-administration of potent ENT1, CNT3, or BCRP transporter inhibitors (e.g., ritonavir, eltrombopag, curcumin, cyclosporine, dilazep, nifedipine, nimodipine, cilostazol, sulindac, dipyridamole, or reserpine) during the 4 to 5 day MAVENCLAD treatment cycles. (bula de Cladribina, Interações medicamentosas)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (bula de Cladribina, Interações medicamentosas)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (bula de Cladribina, Interações medicamentosas)

Antiviral and antiretroviral drugs: Avoid concomitant use. (bula de Cladribina, Interações medicamentosas)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (bula de Cladribina, Interações medicamentosas)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (bula de Cladribina, Interações medicamentosas)

Antiviral and antiretroviral drugs: Avoid concomitant use. (bula de Cladribina, Interações medicamentosas)

Antiviral and antiretroviral drugs: Avoid concomitant use. (bula de Cladribina, Interações medicamentosas)

About 13 percent of the cases of neutropenia have ended fatally, but almost all fatalities were in patients with serious illness, having collagen vascular disease, renal failure, heart failure or immunosuppressant therapy, or a combination of these complicating factors. (bula de Captopril, Advertências)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (bula de Cladribina, Interações medicamentosas)

Prevention or Management Avoid co-administration of potent ENT1, CNT3, or BCRP transporter inhibitors (e.g., ritonavir, eltrombopag, curcumin, cyclosporine, dilazep, nifedipine, nimodipine, cilostazol, sulindac, dipyridamole, or reserpine) during the 4 to 5 day MAVENCLAD treatment cycles. (bula de Cladribina, Interações medicamentosas)

Prevention or Management Avoid co-administration of potent ENT1, CNT3, or BCRP transporter inhibitors (e.g., ritonavir, eltrombopag, curcumin, cyclosporine, dilazep, nifedipine, nimodipine, cilostazol, sulindac, dipyridamole, or reserpine) during the 4 to 5 day MAVENCLAD treatment cycles. (bula de Cladribina, Interações medicamentosas)

Prevention or Management Avoid co-administration of potent ENT1, CNT3, or BCRP transporter inhibitors (e.g., ritonavir, eltrombopag, curcumin, cyclosporine, dilazep, nifedipine, nimodipine, cilostazol, sulindac, dipyridamole, or reserpine) during the 4 to 5 day MAVENCLAD treatment cycles. (bula de Cladribina, Interações medicamentosas)

Antiviral and antiretroviral drugs: Avoid concomitant use. (bula de Cladribina, Interações medicamentosas)

Antiviral and antiretroviral drugs: Avoid concomitant use. (bula de Cladribina, Interações medicamentosas)

Prevention or Management Avoid co-administration of potent ENT1, CNT3, or BCRP transporter inhibitors (e.g., ritonavir, eltrombopag, curcumin, cyclosporine, dilazep, nifedipine, nimodipine, cilostazol, sulindac, dipyridamole, or reserpine) during the 4 to 5 day MAVENCLAD treatment cycles. (bula de Cladribina, Interações medicamentosas)

Antiviral and antiretroviral drugs: Avoid concomitant use. (bula de Cladribina, Interações medicamentosas)

Antiviral and antiretroviral drugs: Avoid concomitant use. (bula de Cladribina, Interações medicamentosas)

Antiviral and antiretroviral drugs: Avoid concomitant use. (bula de Cladribina, Interações medicamentosas)

Antiviral and antiretroviral drugs: Avoid concomitant use. (bula de Cladribina, Interações medicamentosas)

Prevention or Management Avoid co-administration of potent ENT1, CNT3, or BCRP transporter inhibitors (e.g., ritonavir, eltrombopag, curcumin, cyclosporine, dilazep, nifedipine, nimodipine, cilostazol, sulindac, dipyridamole, or reserpine) during the 4 to 5 day MAVENCLAD treatment cycles. (bula de Cladribina, Interações medicamentosas)

Antiviral and antiretroviral drugs: Avoid concomitant use. (bula de Cladribina, Interações medicamentosas)

Antiviral and antiretroviral drugs: Avoid concomitant use. (bula de Cladribina, Interações medicamentosas)

Antiviral and antiretroviral drugs: Avoid concomitant use. (bula de Cladribina, Interações medicamentosas)

Antiviral and antiretroviral drugs: Avoid concomitant use. (bula de Cladribina, Interações medicamentosas)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (bula de Cladribina, Interações medicamentosas)

Antiviral and antiretroviral drugs: Avoid concomitant use. (bula de Cladribina, Interações medicamentosas)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (bula de Cladribina, Interações medicamentosas)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (bula de Cladribina, Interações medicamentosas)

Chicken pox and measles, for example, can have a more serious or even fatal course in children on immunosuppressant corticosteroids. (bula de Fludrocortisona, Advertências)

Persons who are on immunosuppressant doses of corticosteroids should be warned to avoid exposure to chickenpox or measles. (bula de Flunisolida, Precauções)

Antiviral and antiretroviral drugs: Avoid concomitant use. (bula de Cladribina, Interações medicamentosas)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (bula de Cladribina, Interações medicamentosas)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (bula de Cladribina, Interações medicamentosas)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (bula de Cladribina, Interações medicamentosas)

Immunosuppressants Everolimus Sirolimus Temsirolimus (IV) Not recommended during and 2 weeks after TOLSURA treatment. (bula de Itraconazol, Interações medicamentosas)

Antiviral and antiretroviral drugs: Avoid concomitant use. (bula de Cladribina, Interações medicamentosas)

Antiviral and antiretroviral drugs: Avoid concomitant use. (bula de Cladribina, Interações medicamentosas)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (bula de Cladribina, Interações medicamentosas)

Antiviral and antiretroviral drugs: Avoid concomitant use. (bula de Cladribina, Interações medicamentosas)

Prevention or Management Avoid co-administration of potent ENT1, CNT3, or BCRP transporter inhibitors (e.g., ritonavir, eltrombopag, curcumin, cyclosporine, dilazep, nifedipine, nimodipine, cilostazol, sulindac, dipyridamole, or reserpine) during the 4 to 5 day MAVENCLAD treatment cycles. (bula de Cladribina, Interações medicamentosas)

Antiviral and antiretroviral drugs: Avoid concomitant use. (bula de Cladribina, Interações medicamentosas)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (bula de Cladribina, Interações medicamentosas)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (bula de Cladribina, Interações medicamentosas)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (bula de Cladribina, Interações medicamentosas)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (bula de Cladribina, Interações medicamentosas)

Antiviral and antiretroviral drugs: Avoid concomitant use. (bula de Cladribina, Interações medicamentosas)

Prevention or Management Avoid co-administration of potent ENT1, CNT3, or BCRP transporter inhibitors (e.g., ritonavir, eltrombopag, curcumin, cyclosporine, dilazep, nifedipine, nimodipine, cilostazol, sulindac, dipyridamole, or reserpine) during the 4 to 5 day MAVENCLAD treatment cycles. (bula de Cladribina, Interações medicamentosas)

Prevention or Management Avoid co-administration of potent ENT1, CNT3, or BCRP transporter inhibitors (e.g., ritonavir, eltrombopag, curcumin, cyclosporine, dilazep, nifedipine, nimodipine, cilostazol, sulindac, dipyridamole, or reserpine) during the 4 to 5 day MAVENCLAD treatment cycles. (bula de Cladribina, Interações medicamentosas)

Prevention or Management Avoid co-administration of potent ENT1, CNT3, or BCRP transporter inhibitors (e.g., ritonavir, eltrombopag, curcumin, cyclosporine, dilazep, nifedipine, nimodipine, cilostazol, sulindac, dipyridamole, or reserpine) during the 4 to 5 day MAVENCLAD treatment cycles. (bula de Cladribina, Interações medicamentosas)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (bula de Cladribina, Interações medicamentosas)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (bula de Cladribina, Interações medicamentosas)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (bula de Cladribina, Interações medicamentosas)

Antiviral and antiretroviral drugs: Avoid concomitant use. (bula de Cladribina, Interações medicamentosas)

Antiviral and antiretroviral drugs: Avoid concomitant use. (bula de Cladribina, Interações medicamentosas)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (bula de Cladribina, Interações medicamentosas)

Prevention or Management Avoid co-administration of potent ENT1, CNT3, or BCRP transporter inhibitors (e.g., ritonavir, eltrombopag, curcumin, cyclosporine, dilazep, nifedipine, nimodipine, cilostazol, sulindac, dipyridamole, or reserpine) during the 4 to 5 day MAVENCLAD treatment cycles. (bula de Cladribina, Interações medicamentosas)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (bula de Cladribina, Interações medicamentosas)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (bula de Cladribina, Interações medicamentosas)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (bula de Cladribina, Interações medicamentosas)

Prevention or Management Avoid co-administration of potent ENT1, CNT3, or BCRP transporter inhibitors (e.g., ritonavir, eltrombopag, curcumin, cyclosporine, dilazep, nifedipine, nimodipine, cilostazol, sulindac, dipyridamole, or reserpine) during the 4 to 5 day MAVENCLAD treatment cycles. (bula de Cladribina, Interações medicamentosas)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (bula de Cladribina, Interações medicamentosas)

Antiviral and antiretroviral drugs: Avoid concomitant use. (bula de Cladribina, Interações medicamentosas)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (bula de Cladribina, Interações medicamentosas)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (bula de Cladribina, Interações medicamentosas)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (bula de Cladribina, Interações medicamentosas)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (bula de Cladribina, Interações medicamentosas)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (bula de Cladribina, Interações medicamentosas)

Antiviral and antiretroviral drugs: Avoid concomitant use. (bula de Cladribina, Interações medicamentosas)

Frequent PT/INR determinations are advisable until it has been definitely determined that the PT/INR has stabilized Immunosuppressants Clinical Impact: Immunosuppressants such as cyclosporine and tacrolimus can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route… (bula de Ácido fenofíbrico, Interações medicamentosas)

Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (bula de Anlodipino, Interações medicamentosas)

Impact of Amlodipine on Other Drugs Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (bula de Anlodipino + atorvastatina, Interações medicamentosas)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (bula de Anlodipino + olmesartana, Interações medicamentosas)

Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when coadministered. (bula de Anlodipino + valsartana, Interações medicamentosas)

Prevention or Management Consider a possible decrease in cladribine efficacy if potent BCRP (e.g., corticosteroids) or P-gp (e.g., rifampicin, St. (bula de Cladribina, Interações medicamentosas)

Prevention or Management Consider a possible decrease in cladribine efficacy if potent BCRP (e.g., corticosteroids) or P-gp (e.g., rifampicin, St. (bula de Cladribina, Interações medicamentosas)

Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (bula de Bendamustina, Advertências e precauções)

Prevention or Management Consider a possible decrease in cladribine efficacy if potent BCRP (e.g., corticosteroids) or P-gp (e.g., rifampicin, St. (bula de Cladribina, Interações medicamentosas)

Prevention or Management Consider a possible decrease in cladribine efficacy if potent BCRP (e.g., corticosteroids) or P-gp (e.g., rifampicin, St. (bula de Cladribina, Interações medicamentosas)

Prevention or Management Consider a possible decrease in cladribine efficacy if potent BCRP (e.g., corticosteroids) or P-gp (e.g., rifampicin, St. (bula de Cladribina, Interações medicamentosas)

Immunosuppressants everolimus, rapamycin (also known as sirolimus), temsirolimus budesonide, ciclesonide, cyclosporine, dexamethasone, fluticasone, methylprednisolone, tacrolimus Rapamycin (sirolimus): Ketoconazole tablets 200 mg daily for 10 days increased the C max and AUC of a single 5 mg dose of sirolimus by 4.3 fold and 10.9 fold, respectively in 23 healthy… (bula de Cetoconazol, Interações medicamentosas)

Prevention or Management Consider a possible decrease in cladribine efficacy if potent BCRP (e.g., corticosteroids) or P-gp (e.g., rifampicin, St. (bula de Cladribina, Interações medicamentosas)

Prevention or Management Consider a possible decrease in cladribine efficacy if potent BCRP (e.g., corticosteroids) or P-gp (e.g., rifampicin, St. (bula de Cladribina, Interações medicamentosas)

Prevention or Management Consider a possible decrease in cladribine efficacy if potent BCRP (e.g., corticosteroids) or P-gp (e.g., rifampicin, St. (bula de Cladribina, Interações medicamentosas)

Other risk factors for the development of ONJ include immunosuppressive therapy, treatment with angiogenesis inhibitors, systemic corticosteroids, diabetes, and gingival infections. (bula de Denosumabe, Advertências e precauções)

Prevention or Management Consider a possible decrease in cladribine efficacy if potent BCRP (e.g., corticosteroids) or P-gp (e.g., rifampicin, St. (bula de Cladribina, Interações medicamentosas)

Prevention or Management Consider a possible decrease in cladribine efficacy if potent BCRP (e.g., corticosteroids) or P-gp (e.g., rifampicin, St. (bula de Cladribina, Interações medicamentosas)

Immunosuppressants Clinical Impact: Immunosuppressants such as cyclosporine and tacrolimus can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs including fenofibrate, there is a risk that an interaction will lead to deterioration of renal… (bula de Fenofibrato, Interações medicamentosas)

Prevention or Management Consider a possible decrease in cladribine efficacy if potent BCRP (e.g., corticosteroids) or P-gp (e.g., rifampicin, St. (bula de Cladribina, Interações medicamentosas)

Prevention or Management Consider a possible decrease in cladribine efficacy if potent BCRP (e.g., corticosteroids) or P-gp (e.g., rifampicin, St. (bula de Cladribina, Interações medicamentosas)

Prevention or Management Consider a possible decrease in cladribine efficacy if potent BCRP (e.g., corticosteroids) or P-gp (e.g., rifampicin, St. (bula de Cladribina, Interações medicamentosas)

Prevention or Management Consider a possible decrease in cladribine efficacy if potent BCRP (e.g., corticosteroids) or P-gp (e.g., rifampicin, St. (bula de Cladribina, Interações medicamentosas)

Prevention or Management Consider a possible decrease in cladribine efficacy if potent BCRP (e.g., corticosteroids) or P-gp (e.g., rifampicin, St. (bula de Cladribina, Interações medicamentosas)

HBV reactivation has also been reported in patients receiving certain immunosuppressants or chemotherapeutic agents; the risk of HBV reactivation associated with treatment with HCV direct-acting antivirals may be increased in these patients. (bula de Ledipasvir + sofosbuvir, Advertências e precauções)

Prevention or Management Consider a possible decrease in cladribine efficacy if potent BCRP (e.g., corticosteroids) or P-gp (e.g., rifampicin, St. (bula de Cladribina, Interações medicamentosas)

Prevention or Management Consider a possible decrease in cladribine efficacy if potent BCRP (e.g., corticosteroids) or P-gp (e.g., rifampicin, St. (bula de Cladribina, Interações medicamentosas)

Immunosuppressive Agents There have been reports of increased blood concentrations of cyclosporine and tacrolimus into toxic ranges when patients received these drugs concomitantly with nefazodone. (bula de Nefazodona, Interações medicamentosas)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

Prevention or Management Consider a possible decrease in cladribine efficacy if potent BCRP (e.g., corticosteroids) or P-gp (e.g., rifampicin, St. (bula de Cladribina, Interações medicamentosas)

Treatment has consisted of high doses of corticosteroids alone or, in some cases, concomitantly with an immunosuppressant. (bula de Penicilamina, Advertências)

Prevention or Management Consider a possible decrease in cladribine efficacy if potent BCRP (e.g., corticosteroids) or P-gp (e.g., rifampicin, St. (bula de Cladribina, Interações medicamentosas)

Prevention or Management Consider a possible decrease in cladribine efficacy if potent BCRP (e.g., corticosteroids) or P-gp (e.g., rifampicin, St. (bula de Cladribina, Interações medicamentosas)

Glipizide Decrease exposure Immunosuppressive Agents Cyclosporine Decrease exposure Tacrolimus Prevention or Management: Monitoring of whole blood concentrations and appropriate dosage adjustments of tacrolimus are recommended when rifampin and tacrolimus are used concomitantly. (bula de Rifampicina, Interações medicamentosas)

…Digoxin Corticosteroids Prednisone Fibrates Clofibrate Oral Hypoglycemics Sulfonylureas (e.g., glyburide, glipizide) Hormonal Contraceptives/Progestins Ethinyl estradiol, levonorgestrel Immunosuppressants Cyclosporine, tacrolimus Methylxanthines Theophylline Narcotic analgesics Methadone Phosphodiesterase-5 (PDE-5) Inhibitors Sildenafil Thyroid preparations Levothyroxine… (bula de Rifapentina, Interações medicamentosas)

HBV reactivation has also been reported in patients receiving certain immunosuppressant or chemotherapeutic agents; the risk of HBV reactivation associated with treatment with HCV direct-acting antivirals may be increased in these patients. (bula de Sofosbuvir + velpatasvir, Advertências e precauções)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (bula de Telmisartana + anlodipino, Interações medicamentosas)

Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (bula de Tensirolimo, Advertências e precauções)

Cyclosporine, tacrolimus: Monitor for toxicities of these immunosuppressive drugs ( 7.1 ) (bula de Tinidazol, Interações medicamentosas)

Prevention or Management Consider a possible decrease in cladribine efficacy if potent BCRP (e.g., corticosteroids) or P-gp (e.g., rifampicin, St. (bula de Cladribina, Interações medicamentosas)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persists despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (bula de Atorvastatina, Advertências e precauções)

Thirty-four patients were treated with corticosteroids and one patient was treated with a non-steroidal immunosuppressant. (bula de Axitinibe, Advertências e precauções)

Prevention or Management Avoid co-administration of potent ENT1, CNT3, or BCRP transporter inhibitors (e.g., ritonavir, eltrombopag, curcumin, cyclosporine, dilazep, nifedipine, nimodipine, cilostazol, sulindac, dipyridamole, or reserpine) during the 4 to 5 day MAVENCLAD treatment cycles. (bula de Cladribina, Interações medicamentosas)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy without significant inflammation; and improvement with immunosuppressive agents. (bula de Ezetimiba + sinvastatina, Advertências e precauções)

IMNM is characterized by proximal muscle weakness and elevated serum CK, which persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody, muscle biopsy showing necrotizing myopathy, and improvement with immunosuppressive agents. (bula de Fluvastatina, Advertências e precauções)

IMNM is characterized by: proximal muscle weakness and elevated serum creatine kinase, which persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (bula de Lovastatina, Advertências)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (bula de Pitavastatina, Advertências e precauções)

CYP3A Substrates Immunosuppressants that are CYP3A4 Substrates Mechanism and Clinical Effect(s) Posaconazole is a strong CYP3A4 inhibitor. (bula de Posaconazol, Interações medicamentosas)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (bula de Pravastatina, Advertências e precauções)

In some cases, vasculitis resolved/improved with drug discontinuation; however, more severe cases required treatment with additional measures including corticosteroids, immunosuppressant therapy, and plasmapheresis. (bula de Propiltiouracila, Advertências)

Antiviral and Antiretroviral Drugs Clinical Impact Compounds that require intracellular phosphorylation to become active (e.g., lamivudine, zalcitabine, ribavirin, stavudine, and zidovudine) could interfere with the intracellular phosphorylation and activity of cladribine. (bula de Cladribina, Interações medicamentosas)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (bula de Rosuvastatina, Advertências e precauções)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy without significant inflammation; and improvement with immunosuppressive agents. (bula de Sinvastatina, Advertências e precauções)

Prevention or Management Avoid co-administration of potent ENT1, CNT3, or BCRP transporter inhibitors (e.g., ritonavir, eltrombopag, curcumin, cyclosporine, dilazep, nifedipine, nimodipine, cilostazol, sulindac, dipyridamole, or reserpine) during the 4 to 5 day MAVENCLAD treatment cycles. (bula de Cladribina, Interações medicamentosas)

In some cases, vasculitis resolved/improved with drug discontinuation; however, more severe cases required treatment with additional measures including corticosteroids, immunosuppressant therapy, and plasmapheresis. (bula de Tiamazol (metimazol), Advertências)

Prevention or Management Avoid co-administration of potent ENT1, CNT3, or BCRP transporter inhibitors (e.g., ritonavir, eltrombopag, curcumin, cyclosporine, dilazep, nifedipine, nimodipine, cilostazol, sulindac, dipyridamole, or reserpine) during the 4 to 5 day MAVENCLAD treatment cycles. (bula de Cladribina, Interações medicamentosas)

…Repaglinide, Rosiglitazone: [See Warnings and Precautions ( 5.4 ) and Adverse Reactions ( 6.2 )] Insulin Insulin: [See Warnings and Precautions ( 5.4 ) and Adverse Reactions ( 6.2 )] Immunosuppressants: Cyclosporine Use With Caution Cyclosporine: There have been spontaneous or published reports of CYP3A based interactions of clarithromycin with cyclosporine. (bula de Claritromicina, Interações medicamentosas)